Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors


NCT00374660

Interventional

Phase 1/Phase 2

Unknown status
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
Jun 30,2003
All
18 Years
N/A
63

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.